Clinical development of trastuzumab in breast cancer

Breast Cancer

Volumn 8, Issue 2, 2001, Pages 93-97

  Tokuda, Yutaka ^a   Ohta, Masatoshi ^a   Suzuki, Yasuhiro ^a   Kubota, Mitsuhiro ^a   Tajima, Tomoo ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; HER2 neu; Humanized monoclonal antibody; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL; BREAST TUMOR; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY;

EID: 0035230324     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967486     Document Type: Review

References (28)

1. Yarden Y, Ullrich A: Growth factor receptor tyrosine kinases. Annu Rev Biochem 57:443-478, 1988.
2. Coussens L, Yang-Feng TL, Iiao Y-C, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985. (Pubitemid 16169997)
3. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by human c-erbB-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986 (Pubitemid 16128786)
4. King CR, Kraus MH, Aronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976, 1985. (Pubitemid 16248488)
5. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989. (Pubitemid 19147683)
6. De Porer CR, Van Daele S, Van De Vijver MJ, et al: The expression of the neu oncogene in breast lesions and in normal fetal and adult human tissues. Histopathology 15:315-326, 1989.
7. Prss MF, Cerdon-Cardo C, Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953-962, 1990.
8. Drebin JA, Link VC, Stern DF, et al: Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695-706, 1985. (Pubitemid 15243377)
9. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitized human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172, 1989. (Pubitemid 19071685)
10. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumour cell lines. Cancer Res 51:4575-4580, 1991.
11. Stancovski I, Hurwitz E, Leitner O, et al: Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB-2 receptor on tumor growth. Proc Natl Acad Sci USA 88:8691-8695, 1991. (Pubitemid 21915423)
12. HER2 and growth inhibition of cells with HER2/neu gene amplification. Int J Cancer 47:933-937, 1991.
13. Harwerth I-M, Wels W, Marte BM, et al: Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 267:15160-15167, 1992.
14. Kasprzyk PG, Song SU, Di Fiore PP, et al: Therapy of an animal model of human gastric cancer using a combination of anti-er6B-2monoclonal antibodies. Cancer Res 52:2771-2776, 1992.
15. Schroff RW, Foon KA, Beatty SM, et al: Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879-885, 1985. (Pubitemid 15161095)
16. Ohnish Y, Nakamura H, Yoshimura M, et al: Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antibody. Br J Cancer 71:969-973, 1995.
17. Shawler DL, Bartholomew RM, Smith LM, et al: Human immune response to multiple injection of murine monoclonal IgG. J Immunol 135:1530-1535, 1985. (Pubitemid 16237070)
18. HEB2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289, 1992.
19. Tokuda Y, Ohnish Y, Shimamura K, et al: In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73:1362-1365, 1996. (Pubitemid 26175668)
20. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999. (Pubitemid 29415219)
21. Tokuda Y, Watanabe T, Omuro Y, et al: Dose escalation and pharmacokinetic study of a humanised anti-HER2 monoclonal antibody in patients with HER2/neu-over-expressing metastatic breast cancer. Br J Cancer 81:1419-1425, 1999.
22. Vogel C, Cobleigh M, Tripathy D, et al: First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 19:71a, 2000(abstr 275).
23. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999. (Pubitemid 29186925)
24. ™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 +/MBC) markedly increase anticancer activity: a randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998(abstr 377).
25. Seidman A, Fornier M, Esteva F, et al: Final report: weekly (W) Herceptin and Taxol (T) for metastatic breast cancer (MBC): analysis of efficacy by HER2 immunophenotype (immunohistochemistry (IHQ) and gene amplification (fluorescent in-situ hybridization (FISH)). Proc Am Soc Clin Oncol 19:83a, 2000(abstr 319).
26. Burstein H, Kuter I, Richardson P, et al: Herceptin and vinorelbine for HER22-positive metastatic breast cancer: a phase II study. Proc Am Soc Clin Oncol 19:102a, 2000(abstr 392).
27. Mass RD, Sanders C, Charlene K, et al: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 19:75a, 2000(abstr 291).
28. Buehler H, Bangemann N, Evers K, et al: Effective HER-2/neu diagnosis in breast cancer by a combination of immunohistochemistry and FISH. Proc Am Soc Clin Oncol 19:76a, 2000(abstr 294).